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Summary
Small, dense LDL particles consistently have been as-
sociated with hypertriglyceridemia, premature coronary
artery disease (CAD), and familial combined hyperlipi-
demia (FCH). Previously, we have observed linkage of
LDL particle size with four separate candidate-gene loci
in a study of families enriched for CAD. These loci con-
tain the genes for manganese superoxide dismutase
(MnSOD), on chromosome 6q; for apolipoprotein AI-
CIII-AIV, on chromosome 11q; for cholesteryl ester
transfer protein (CETP) and lecithin:cholesterol acyl-
transferase (LCAT), on chromosome 16q; and for the
LDL receptor (LDLR), on chromosome 19p. We have
now tested whether these loci also contribute to LDL
particle size in families ascertained for FCH. The mem-
bers of 18 families (481 individuals) were typed for ge-
netic markers at the four loci, and linkage to LDL par-
ticle size was assessed by nonparametric sib-pair linkage
analysis. The presence of small, dense LDL (pattern B)
was much more frequent in the FCH probands (39%)
than in the spouse controls (4%). Evidence for linkage
was observed at the MnSOD ( ), CETP/LCATP  .02
( ), and apolipoprotein AI-CIII-AIV loci (P  .03 P 
) but not at the LDLR locus. We conclude that there.005
is a genetically based association between FCH and
small, dense LDL and that the genetic determinants for
LDL particle size are shared, at least in part, among FCH
families and the more general population at risk for
CAD.
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Introduction
Familial combined hyperlipidemia (FCH [MIM
144250]), the most common genetic dyslipidemia in
man, affects 1%–2% of the population and occurs in
10%–20% of premature myocardial-infarction sur-
vivors (Goldstein et al. 1973). It is believed that the
primary metabolic defect in FCH leads to hepatic over-
production of apolipoprotein B-100–containing lipo-
proteins—namely, very-low-density lipoprotein (VLDL)
and LDL—resulting in elevated plasma cholesterol and/
or triglycerides levels (Cortner et al. 1991; Venkatesan
et al. 1993). FCH was first postulated to segregate as
an autosomal dominant trait, but there is increasing ev-
idence that it is an oligogenic disorder with a complex
pattern of inheritance (Williams and Lalouel 1982; Cul-
len et al. 1994; Jarvik et al. 1994; Bredie et al. 1996).
The primary genetic factors underlying FCH have yet to
be identified.
Frequently, but not always, certain other traits also
occur in patients with FCH, although they are not con-
sidered as criteria for the diagnosis of disease. These
traits include reduced levels of HDL (Grundy et al. 1987;
Castro Cabezas et al. 1993) and a preponderance of
small, dense LDL particles (Austin et al. 1990a; Jarvik
et al. 1994). The presence of such dense LDL particles,
which occurs in combination with increased plasma tri-
glycerides and apolipoprotein B (apoB) concentrations
and with reduced HDL-cholesterol levels, has been
termed the “atherogenic lipoprotein phenotype” (ALP)
and is independently associated with an increased risk
for coronary artery disease (CAD) (Austin et al. 1988a).
Moreover, it has been suggested that hyperapobetali-
poproteinemia (hyperapoB), defined as an increased
apoB:LDL-cholesterol (apoB:LDL-C) ratio, reflects the
presence of FCH in affected individuals (Sniderman et
al. 1980). However, it is unclear whether the associations
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Table 1
Oligonucleotides and Conditions Used for Radiation-Hybrid Mapping of Candidate Genes
Candidate
Gene Sequencea
Annealing
Temperature
(C)
Product
Size
(bp) Reference
CETP:
Forward 5′-TCATGAACAGCAAAGGCGTGAGCCTCTTCG-3′ 58 180 Sakai et al. (1995)
Reverse 5′-AGCCAAGCTGGTAGAGGCCCCTCTGTCTGT-3′
LCAT:
Forward 5′-CGACAGCCCAGTGCCGCTTTCTCTG-3′ 56 206 Skretting and Prydz (1992)
Reverse 5′-GGCTTACCGAGGATGACGGGCCGTG-3′
MnSOD:
Forward 5′-CGACCTGCCCTACGACTACG-3′ 58 549 )
Reverse 5′-CACACCTACCTGAGAGACCAAACA-3′
a For LCAT and CETP, previously published oligonucleotides were used for radiation-hybrid mapping; for MnSOD, new
oligonucleotides were designed from the genomic sequence, by means of the OLIGO 4.0 program.
between these traits and FCH are the result of common
underlying metabolic defects or are separate entities.
In previous studies with families enriched for CAD,
we have obtained evidence of linkage of the presence of
small, dense LDL particles to four separate candidate-
gene loci: the LDL receptor (LDLR) gene on chromo-
some 19p, the apoAI-CIII-AIV gene cluster on chro-
mosome 11q, the cholesteryl ester–transfer protein/
lecithin:cholesterol acyltransferase (CETP/LCAT) locus
on chromosome 16q, and the manganese superoxide dis-
mutase (MnSOD) locus on chromosome 6q (Nishina et
al. 1992; Rotter et al. 1996). In the present study, we
sought to test whether these same loci contribute to ei-
ther LDL particle size or related phenotypes in families
with FCH. The results indicate that the MnSOD, CETP/
LCAT, and AI-CIII-AIV loci exhibit evidence of linkage,
whereas the LDLR locus failed to show significant evi-
dence of linkage. Furthermore, the presence of small,
dense LDL particles was 10-fold greater in FCH pro-
bands than in spouses, strengthening the frequently ob-
served association between FCH and ALP. These results
provide supportive evidence that the MnSOD, CETP/
LCAT, and AI-CIII-AIV loci contribute to LDL particle
size, and they suggest that ALP and FCH share a subset
of their genetic determinants.
Subjects and Methods
Ascertainment of FCH Families
Eighteen unrelated Dutch Caucasian index FCH pa-
tients were ascertained through family members re-
cruited from the Lipid Clinic of University Hospital
(Utrecht). These subjects met the criteria described else-
where (Goldstein et al. 1973; Brunzell et al. 1983; Castro
Cabezas et al. 1993): first, a primary hyperlipidemia with
varying phenotypic expression, including a fasting
plasma cholesterol concentration 1250 mg/dl (6.5 mmol/
liter), or above the 95th percentile for age (defined ac-
cording to the tables from the Lipid Research Clinics),
and/or fasting plasma triglyceride concentration 1200
mg/dl (2.3 mmol/liter) and elevated plasma apoB con-
centrations, exceeding, by x2 SDs, the mean for age-
adjusted levels; second, at least one first-degree relative
with a hyperlipidemic phenotype different from that of
the proband; third, a positive family history of prema-
ture CAD, defined as myocardial infarction or cerebro-
vascular disease at age !60 years in either at least one
blood-related subject or the index patient; and fourth,
absence of xanthomas. Exclusion criteria included dia-
betes, familial hypercholesterolemia (absence of isolated
elevated plasma LDL-C levels and tendon xanthomas),
and type III hyperlipidemia (apoE2/E2 genotype). All
subjects gave informed consent, and the study protocol
was approved by the Human Investigation Review Com-
mittee of University Hospital (Utrecht).
Relatives were assigned the FCH phenotype when they
met the following criteria: plasma cholesterol levels 1250
mg/dl, plasma triglycerides 1200 mg/dl, and/or plasma
apoB levels above the 75th percentile. Under these cri-
teria, there were 151 affected individuals and 176 un-
affected relatives. The spouses ( ) represented an  154
common, environment-, nutrition-, and age-matched
control group for the probands and their hyperlipidemic
relatives.
Biochemical Analyses
Venous blood was drawn after an overnight fast of
12–14 h and abstention from alcohol consumption for
x48 h. Plasma was prepared by immediate centrifu-
gation and was stored at70C until the analysis. Lipids
and apolipoproteins were quantified according to meth-
odology described elsewhere (Castro Cabezas et al.
1993; Dallinga-Thie et al. 1997). LDL subclass distri-
butions were analyzed after nondenaturing gradient gel
electrophoresis of plasma in 2%–16% polyacrylamide
gradient gels with lipid staining and densitometric scan-
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Table 2
Candidate Genes and Linked Polymorphic Markers Assessed for
Linkage to ALP
Candidate Gene
and Markera
Hetero-
zygosity
Chromo-
some Reference
AI-CIII-AIV:
XMS .41 11 Dallinga-Thie et al. (1996)
CETP/LCAT:
D16S408 .69 16
D16S514 .82
D16S400 .61
D16S496 .74
LDL-R:
LDLR .48 19 Zuliani and Hobbs (1990)
MnSOD:
D6S1007 .60 6
D6S1008 .77
a Markers for CETP, LCAT, and MnSOD were ascertained through
radiation-hybrid mapping; a previously reported microsatellite was
used for LDL-R; and XMS  haplotype of XmnI, MspI, and SstI
restriction sites within the apoAI-CIII-AIV gene cluster.
ning, as described elsewhere (Nichols et al. 1986; Austin
et al. 1988a, 1988b, 1990b). LDL particle diameters
were calculated from the calibration curves, by means
of protein size standards (Nichols et al. 1986), and the
diameter of the peak of greatest amplitude for each sam-
ple was designated the “peak particle diameter” (PPD).
Qualitative LDL subclass pattern was assigned by cri-
teria described elsewhere (Austin et al. 1988a, 1988b,
1990b). According to the broad definition of the ALP,
we have included intermediate-pattern individuals with
pattern B individuals and have defined this group col-
lectively as being affected with ALP (Rotter et al. 1996).
Radiation-Hybrid Mapping
Polymorphic microsatellite markers for candidate
genes were ascertained through radiation-hybrid map-
ping (Walter et al. 1994) using the Genebridge 4 Ra-
diation Hybrid screening panel (Research Genetics). In
brief, oligonucleotides corresponding to a region of each
candidate gene (Skretting and Prydz 1992; Sakai et al.
1995) were used to screen the radiation-hybrid panel by
means of PCR amplification of hybrid-cell-line DNA
(table 1). The data were entered into a software program
at the Whitehead Institute/MIT Center for Genome Re-
search, for mapping. Polymorphic microsatellites an-
chored on both a genetic and radiation-hybrid map were
chosen so as to flank the candidate gene in the smallest
interval possible. These markers were then used for sub-
sequent linkage studies. Reaction conditions were as fol-
lows: 50 ng of the cell-line DNA, 0.70 mM of each oli-
gonucleotide, 1.5 mM MgCl2, 100 mM of each dNTP
(Gibco BRL), and 0.5 U of Taq polymerase (Gibco BRL)
and 35 cycles at 94C for 30 s, 56C or 58C for 30 s,
and 72C for 45 s. PCR products were resolved on 2%
agarose gels.
Genotyping
DNA was isolated from peripheral blood cells and was
typed for polymorphic markers at or flanking the fol-
lowing candidate genes: the apoAI-CIII-AIV gene cluster,
CETP, LCAT, LDLR, and MnSOD. Table 2 provides a
description of the polymorphic markers used in this
study. Microsatellites near CETP, LCAT, and MnSOD
were identified through radiation-hybrid mapping. A
previously identified intragenic marker was used for the
LDLR gene (Zuliani and Hobbs 1990). The apoAI-CIII-
AIV gene cluster was genotyped according to three
RFLPs located upstream of the apoAI gene (XmnI and
MspI) and within the 3′ UTR of exon 4 of the apoCIII
gene (SstI). These RFLPs have been described in detail
elsewhere (Dallinga-Thie et al. 1996).
In total, 481 individuals were genotyped for linkage
analysis. Reaction conditions for microsatellite analysis
were as follows: 75 ng of genomic DNA, 0.34 mM of
each primer (the forward primer was end-labeled with
32P), 200 mM of each dNTP (Gibco BRL), 3.0 mM
MgCl2, and 0.5 U of Taq polymerase (Gibco BRL). PCR
was performed in 96-well plates, with 25 cycles at 94C
for 30 s, 55C for 30 s, and 72C for 45 s. PCR products
were resolved on 5% polyacrylamide gels, blotted with
Whatman paper, and exposed to film overnight. Geno-
types were then assigned to each individual, by two in-
dependent observers.
The presence or absence of the RFLPs within the
apoAI-CIII-AIV gene was determined as described else-
where (Dallinga-Thie et al. 1996). In brief, the region
of DNA encompassing the restriction site was PCR am-
plified by means of site-specific primers and incubated
with the appropriate enzyme at 37C for 1 h, and the
products were resolved on 3% agarose gels. The alleles
of the RFLPs (1 if the restriction site was present, 2 if
it was not present) were constructed into haplotypes to
increase the informativeness of the locus and then were
used for linkage analysis.
Statistical Analysis
Statistical differences in mean trait values between
groups were assessed by unpaired Student’s t-test. Dif-
ferences in the ALP frequency distribution between
groups were assessed by Fisher’s exact test.
Nonparametric Sib-Pair Linkage Analysis
The methodology of robust sib-pair analysis was used
to test whether there is linkage between qualitative and
quantitative traits and a polymorphic marker(s) at each
of the candidate-gene loci (Haseman and Elston 1972;
Amos et al. 1989). By means of the SIBPAL subprogram
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Table 3
Clinical Characteristics of FCH-Family Members
Variable
Hyperlipidemic
Individuals
( )an  151
Normolipidemic
Individuals
( )n  176
Spouse
Controls
( )n  154
Age (years) 47  15 31  13 49  16
Cholesterol (mg/dl) 281  72 190  32 220  41
LDL-C (mg/dl) 183  46 120  29 144  38
HDL-C (mg/dl) 43  11 48  12 48  12
Triglycerides (mg/dl) 210  107 112  47 142  78
apoB (mg/dl) 143  27 91  20 110  27
apoB:LDL-C ratiob 175  56 164  23 167  37
NOTE.—Values are expressed as mean  SD.
a Includes the 18 probands and 133 hyperlipidemic relatives.
b Plasma apoB:LDL-C ratio multiplied by 1,000. The ratio is a sur-
rogate marker for hyperapoB.
Figure 1 Distribution of PPD in study population
in the S.A.G.E. package (S.A.G.E. 1997), all quantitative
traits were evaluated for linkage with marker loci, by
regressing the squared trait difference of sib pairs on the
proportion of alleles shared identical by descent (IBD).
If there is no linkage between the trait and the marker
locus, the squared trait difference is expected to be rel-
atively constant, regardless of the proportion of marker
alleles shared IBD. Hence, the slope of the regression
line should not be significantly different from zero. In
the presence of linkage, however, the squared trait dif-
ference is expected to be decreased when the siblings
share a greater proportion of marker alleles, resulting in
a significant negative slope of this regression line (Hase-
man and Elston 1972). Because sib pairs in the same
sibship may be nonindependent statistically, significance
levels are calculated by means of effective df, which re-
flects the number of independent sib pairs in the analyses
(S.A.G.E. 1997).
For the qualitative trait, ALP, the linkage analysis was
conducted only with sib pairs concordant for the pres-
ence of the ALP trait. The mean proportion of alleles
shared IBD by the affected sib pairs was calculated and
then tested to assess whether it was significantly 1.50,
the expected proportion of marker sharing in the absence
of linkage between the trait and the marker. Since we
were testing specific hypotheses with respect to each of
four candidate genes, we set the threshold for significant
evidence of linkage at for each of these loci.P ! .05
Results
Study Subjects
The clinical characteristics of the FCH probands, their
normolipidemic and hyperlipidemic relatives, and the
spouse controls are summarized in table 3. The hyper-
lipidemic relatives and probands were characterized by
higher levels of total plasma cholesterol, triglycerides,
LDL-C, and apoB and lower HDL levels, compared with
those in the normolipidemic relatives and spouse con-
trols. However, since the FCH phenotype typically is not
manifested until the 2d decade of life, it cannot be ex-
cluded that some of the normolipidemic relatives have
yet to fully express the disease trait. In addition, the
apoB:LDL-C ratio also was higher in the hyperlipidemic
relatives than in the normolipidemic relatives and spouse
controls (table 3).
Identification of Informative Genetic Markers for
Candidate Genes
In a previous study, we had assessed linkage of the
MnSOD and CETP gene loci to LDL particle size by
using either RFLPs or a microsatellite marker that
mapped 6 cM from CETP (Rotter et al. 1996). In the
present study, we precisely placed the CETP, LCAT, and
MnSOD genes on their respective chromosomes, relative
to previously mapped microsatellites markers, using the
radiation-hybrid system. The advantage of this approach
is twofold: first, microsatellites that are anchored on
both the physical radiation-hybrid map and a genetic
map can be chosen so as to flank the candidate gene in
a small interval, thereby providing the best assessment
of linkage; second, microsatellites have high heterozy-
gosity indices and therefore are particularly informative
for linkage studies. For the CETP, LCAT, and MnSOD
genes, two flanking microsatellites were chosen, with
heterozygosity indices of .61–.82. The CETP and LCAT
genes mapped in close proximity (!10 cM) to each other,
and the linkage results could not, with absolute certainty,
be assigned to one gene or the other. Therefore, in the
present report, this candidate region is referred to as the
“CETP/LCAT locus” and will be considered as one
locus.
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Table 4
Distribution of LDL Subclass Patterns and
Their PPDs in the Study Population
LDL Subclass No. (%)
PPD  SD
(A˚)
Pattern A 385 (85) 274  6
Intermediate pattern 21 (5) 261  2
Pattern B 45 (10) 251  6
Table 5
Association between ALP and FCH Affection Status
ALP STATUS
NO. (%) OF INDIVIDUALS WITH ALP
Spouses Probands Total
Absent 138 (96) 11 (61) 149
Present 6 (4)∗ 7 (39)∗ 13
Total 144 18 162
Unaffected
Relativesa
Affected
Relatives
Absent 292 (97) 110 (75) 402
Present 9 (3) 36 (25) 45
Total 301 146 447
a Spouse controls and normolipidemic relatives were included
within the group of unaffected relatives, since there were no differences
in their mean PPDs.
∗ (difference between probands with ALP and spouse con-P ! .0001
trols with ALP, by Fisher’s exact test). Under the broad definition of
ALP, individuals with an intermediate pattern were grouped with pat-
tern B individuals.
Analysis of Linkage of Four Candidate Genes to LDL
Particle Size
The distribution of peak LDL particle size in the FCH
families, as measured by gradient gel electrophoresis, is
shown in figure 1. Table 4 shows both the distribution
of the PPD for each subclass pattern and the number of
individuals in each category. A total of 451 family mem-
bers were phenotyped for plasma LDL particle size. Sig-
nificantly, there was a 10-fold–higher prevalence of ALP
in the FCH probands than in the spouse controls (39%
vs. 4%; ) (table 5), consistent with the conceptP ! .0001
that FCH and ALP exhibit common genetic and envi-
ronmental determinants (Austin et al. 1990a; Jarvik et
al. 1994). A similar trend also was observed when all
family members were examined, with ALP being present
in 25% of the affected, hyperlipidemic relatives and in
only 3% of the unaffected relatives (table 5).
We conducted quantitative linkage analysis on two
measures of LDL particle size: PPD and apoB:LDL-C
ratio. A qualitative sib-pair linkage analysis with ALP
as a discrete trait also was performed. Since each LDL
particle has one apoB-100 apolipoprotein, the amount
of LDL apoB is reflective of the number of LDL particles.
Therefore, the apoB:LDL-C ratio can be interpreted as
a measure of LDL particle size, in which individuals with
pattern B have a ratio greater than that in individuals
with pattern A. In our FCH population, we utilized mea-
surement of total apoB in plasma as a surrogate for LDL
apoB, and an inverse relationship between PPD and the
apoB:LDL-C ratio was observed ( ) (fig. 2).r  .36
High apoB:LDL-C ratios were defined arbitrarily as
those above the 95th percentile in the spouse controls,
and the highest apoB:LDL-C ratios were found in in-
dividuals with LDL pattern B (fig. 2).
In the quantitative analysis, we obtained evidence of
linkage of PPD and the apoB:LDL-C ratio to the CETP/
LCAT locus (see table 6) but found no evidence of link-
age of these measures to any of the other three loci tested.
With the qualitative trait, ALP, significant evidence for
linkage was observed, with both markers, at the MnSOD
gene locus, as well as with the haplotype of the RFLPs
within the apoAI-CIII-AIV gene cluster (table 7). How-
ever, we did not observe evidence of linkage to the LDLR
locus.
Discussion
Small, dense LDL particles are a characteristic feature
of ALP and hyperapoB, complex phenotypes associated
with increased incidence of CAD. Previous linkage stud-
ies of families from general populations and of families
enriched for CAD have provided evidence for the in-
volvement of four loci contributing to small, dense LDL
particles (Nishina et al. 1992; Rotter et al. 1996). An-
other disorder that has been associated with small, dense
LDL is FCH, a phenotype of “mixed hyperlipidemia”
characterized by hypercholesterolemia, hypertriglyceri-
demia, or both and by a complex pattern of inheritance
with a dramatic familial aggregation. It has, in fact, been
speculated that ALP, hyperapoB, and FCH are manifes-
tations of the same underlying metabolic syndrome (Sni-
derman et al. 1980; Kwiterovich 1993). To further in-
vestigate the relationship between these disorders, we
have examined the association between ALP and FCH
and have tested whether the four loci previously shown
to contribute to small, dense LDL particles in families
ascertained for CAD also contribute to the phenotype
in FCH families. Our results support the involvement of
loci containing the genes for MnSOD, CETP/LCAT, and
apoAI-CIII-AIV—but not the involvement of the locus
containing the gene for LDLR—in FCH-associated ALP.
The results also demonstrate that there is an enrichment
of ALP in FCH-affected individuals, compared with con-
trols. These two lines of data further strengthen the no-
tion that these complex traits are related.
Austin et al. (1988b) initially postulated that the ALP
in normolipidemic families is under the influence of a
major gene, a hypothesis that has also been used to ex-
plain LDL particle size in FCH families (Austin et al.
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Figure 2 Regression plot of PPD and apoB:LDL-C ratio in study
population.
Table 6
Significant Results of Quantitative Sib-Pair Linkage Analysis for
PPD and apoB:LDL-C Ratio: CETP/LCAT Locus
Candidate-Gene
Region Marker
Effective
df P
PPD CETP/LCAT D16S496 132 .035
apoB:LDL-C ratio CETP/LCAT D16S514 146 .031
1990a; Jarvik et al. 1994; Bredie et al. 1996). Using
parametric linkage analysis and assuming incomplete
penetrance, Nishina et al. (1992) obtained evidence of
linkage to the LDLR gene. This finding was confirmed
by a subsequent study using nonparametric analysis in
an independent series of families enriched for CAD;
however, three additional loci—the apoAI-CIII-AIV lo-
cus, the CETP gene locus, and a chromosome 6 locus
containing the MnSOD gene—also were found to be
linked to LDL particle size, suggesting that ALP is under
multigenic control (Rotter et al. 1996).
In the present study, we have obtained evidence sup-
porting the linkage of the CETP/LCAT, MnSOD, and
apoAI-CIII-AIV gene loci to LDL particle size. Since the
CETP and LCAT genes map very close to each other, it
is possible that our previous study (Rotter et al. 1996)
detected linkage with the LCAT gene locus. The results
of our present study, taken together with our previous
findings, suggest that this region of chromosome 16 con-
tains a genetic determinant of LDL particle size. In the
population in the present study, we did not observe link-
age with the LDLR gene locus (Nishina et al. 1992;
Rotter et al. 1996). It is possible that the underlying
defect in FCH alters LDL metabolism in such a way that
ALP in FCH families results from pathways not involv-
ing the contribution of the LDLR gene locus. Alterna-
tively, the effects of the LDLR gene locus may be ob-
scured by the FCH trait itself. Interestingly, in a recent
follow-up study of the original families in which linkage
to this locus had been demonstrated, no mutations in
the coding sequence of the LDLR gene were found, rais-
ing the possibility that the observed effect of this locus
is due to a nearby gene rather than to the LDLR gene
itself (Naggert et al. 1997).
The present study’s observation of linkage of ALP
with the apoAI-CIII-AIV gene cluster is important for
two reasons: first, it supports the role of the apoAI-CIII-
AIV gene cluster as a genetic determinant of LDL particle
size, as observed by Rotter et al. (1996); and, second,
we and others have demonstrated evidence for linkage
of the apoAI-CIII-AIV gene cluster to FCH (Wojcie-
chowski et al. 1991; Dallinga-Thie et al. 1997). Thus,
since the apoAI-CIII-AIV gene cluster demonstrates link-
age to both FCH and ALP, it provides evidence for a
common genetic basis for these traits, which has been
suggested elsewhere (Kwiterovich 1993). Expression of
the apoCIII gene in this cluster has been shown to be a
determinant of plasma VLDL triglyceride levels in mice
(Weinstock et al. 1997). In humans, the apoCIII gene
affects plasma apoCIII concentrations, and the elevated
apoCIII plasma concentrations in FCH subjects predict
impaired postprandial lipemia (Castro-Cabezas et al.
1993; Dallinga-Thie et al. 1996). Furthermore, it is
known that, in general, plasma triglyceride levels are a
determinant of LDL pattern B as well as ALP (Austin
et al. 1988a; Bredie et al. 1997). Therefore, the involve-
ment of the apoCIII gene in ALP and FCH is not only
evident from the linkage results but biologically plau-
sible as well.
LDL particle size presumably is influenced by factors
governing the synthesis, processing, and cellular uptake
of VLDL and its metabolic products. The activities of
CETP and LCAT are dependent on the size of the pool
of triglyceride-rich lipoproteins, a concept that has been
employed to explain the well-known association be-
tween hypertriglyceridemia and reduced HDL levels
(Tall 1986). Other observations indicate that, in some
human populations, hypertriglyceridemia is associated
with elevated levels of small, dense LDL. Given the ev-
idence for linkage between the CETP/LCAT gene locus
and LDL particle size, a similar lipid-exchange mecha-
nism mediated by CETP and LCAT may explain the
generation of small, dense LDL particles in the presence
of an expanded pool of triglyceride-rich lipoproteins.
A biological basis for the linkage of the MnSOD gene
locus with LDL particle size is more speculative. Small,
dense LDL particles have been shown to be more sus-
ceptible to oxidation (de Graaf et al. 1991; Tribble et
al. 1992). It is conceivable that MnSOD influences li-
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Table 7
Results of Sib-Pair Linkage Analysis for ALP
Candidate
Gene Marker
No. of
Affected
Sib Pairs
Mean Allele
Sharing Pa
AI-CIII-AIV XMS 32 .60 .005
MnSOD D6S1007 29 .62 .036
D5S1008 15 .64 .020
LDL-R LDLR 25 .53 NS
a NS  not significant ( ).P 1 .10
poprotein metabolism by effects on mitochondrial fatty-
acid oxidation or acylation. For example, the high fatty-
acid flux that occurs in FCH could result in an elevated
oxidative burden, leading to increased superoxide pro-
duction (Bredie et al. 1997). It also is noteworthy that
MnSOD confers resistance to tumor necrosis factor
(TNF) and that TNF down-regulates lipoprotein lipase
(LPL) expression (Wong et al. 1989). Thus, the decreased
expression of LPL observed in a high fraction of FCH
patients could result from cytokine-mediated effects pos-
sibly involving MnSOD.
In the families in the present study, a low (4%) prev-
alence of ALP or LDL pattern B was observed among
unaffected relatives, resulting in a very high (96%) spec-
ificity of LDL pattern B for the diagnosis of FCH, al-
though sensitivity was only moderate. Austin et al.
(1990a) reported a 29% prevalence of ALP (also mea-
sured as small, dense LDL [pattern B]) in a FCH pop-
ulation comprising 234 affected and unaffected relatives.
Similarly, Jarvik et al. (1994) found a 34.4% prevalence
of small, dense LDL in four FCH pedigrees ( ).n  192
However, in the population of FCH families that we
studied, the prevalence of ALP was only 15%. A rea-
sonable explanation for the observed differences is that
the penetrance of LDL pattern B is dependent on and
can be affected by genetic factors associated with the
FCH phenotype, population differences, and/or envi-
ronmental influences such as diet. Thus, the lack of ob-
served linkage with the LDLR locus also may be attrib-
uted to the lower prevalence of ALP in the population
that we studied, which reduced the number of affected
sib pairs in the analysis.
As a surrogate marker for hyperapoB, the apoB:LDL-
C ratio demonstrated an inverse relationship with LDL
PPD in FCH relatives, and the highest ratios were found
among subjects with small, dense LDL particles (pattern
B). When the ratio was converted to a discrete variable,
with the 95th percentile as a cutoff point, it was observed
to be independent of the presence of FCH, consistent
with the original definition of hyperapoB (data not
shown) (Sniderman et al. 1980). Thus, our results sug-
gest that the apoB:LDL-C ratio, although an informative
measure of LDL particle size, does not appear to be
diagnostic for FCH, a finding consistent with a report
showing the independent segregation of apoB and LDL
particle size in FCH (Jarvik et al. 1994).
In conclusion, our results indicate that three candidate
loci contributing to small, dense LDL particles in the
general population also contribute to this trait in FCH
families. Thus, our results support the hypothesis that
LDL particle size is under multigenic control. We also
demonstrated that the prevalence of small, dense LDL
particles is 10-fold higher in affected FCH individuals.
Taken together, these results provide new insights into
the frequently observed relationship between FCH and
the small-dense-LDL trait, both of which significantly
predispose to CAD.
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